Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation
© 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd..
BACKGROUND: Donor-derived cell free DNA (dd-cfDNA) and gene expression profiling (GEP) offer noninvasive alternatives to rejection surveillance after heart transplantation; however, there is little evidence on the paired use of GEP and dd-cfDNA for rejection surveillance.
METHODS: A single center, retrospective analysis of adult heart transplant recipients. A GEP cohort, transplanted from January 1, 2015 through December 31, 2017 and eligible for rejection surveillance with GEP was compared to a paired testing cohort, transplanted July 1, 2018 through June 30, 2020, with surveillance from both dd-cfDNA and GEP. The primary outcomes were survival and rejection-free survival at 1 year post-transplant.
RESULTS: In total 159 patients were included, 95 in the GEP and 64 in the paired testing group. There were no differences in baseline characteristics, except for less use of induction in the paired testing group (65.6%) compared to the GEP group (98.9%), P < .01. At 1-year, there were no differences between the paired testing and GEP groups in survival (98.4% vs. 94.7%, P = .23) or rejection-free survival (81.3% vs. 73.7% P = .28).
CONCLUSIONS: Compared to post-transplant rejection surveillance with GEP alone, pairing dd-cfDNA and GEP testing was associated with similar survival and rejection-free survival at 1 year while requiring significantly fewer biopsies.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:37 |
|---|---|
| Enthalten in: |
Clinical transplantation - 37(2023), 3 vom: 27. März, Seite e14699 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Henricksen, Erik J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Biomarker |
|---|
| Anmerkungen: |
Date Completed 14.03.2023 Date Revised 18.03.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/ctr.14699 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM340830727 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM340830727 | ||
| 003 | DE-627 | ||
| 005 | 20231226010351.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/ctr.14699 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1136.xml |
| 035 | |a (DE-627)NLM340830727 | ||
| 035 | |a (NLM)35559582 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Henricksen, Erik J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Combining donor derived cell free DNA and gene expression profiling for non-invasive surveillance after heart transplantation |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2023 | ||
| 500 | |a Date Revised 18.03.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd. | ||
| 520 | |a BACKGROUND: Donor-derived cell free DNA (dd-cfDNA) and gene expression profiling (GEP) offer noninvasive alternatives to rejection surveillance after heart transplantation; however, there is little evidence on the paired use of GEP and dd-cfDNA for rejection surveillance | ||
| 520 | |a METHODS: A single center, retrospective analysis of adult heart transplant recipients. A GEP cohort, transplanted from January 1, 2015 through December 31, 2017 and eligible for rejection surveillance with GEP was compared to a paired testing cohort, transplanted July 1, 2018 through June 30, 2020, with surveillance from both dd-cfDNA and GEP. The primary outcomes were survival and rejection-free survival at 1 year post-transplant | ||
| 520 | |a RESULTS: In total 159 patients were included, 95 in the GEP and 64 in the paired testing group. There were no differences in baseline characteristics, except for less use of induction in the paired testing group (65.6%) compared to the GEP group (98.9%), P < .01. At 1-year, there were no differences between the paired testing and GEP groups in survival (98.4% vs. 94.7%, P = .23) or rejection-free survival (81.3% vs. 73.7% P = .28) | ||
| 520 | |a CONCLUSIONS: Compared to post-transplant rejection surveillance with GEP alone, pairing dd-cfDNA and GEP testing was associated with similar survival and rejection-free survival at 1 year while requiring significantly fewer biopsies | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a biomarker | |
| 650 | 4 | |a dysfunction | |
| 650 | 4 | |a graft survival | |
| 650 | 4 | |a heart (allograft) function | |
| 650 | 4 | |a rejection | |
| 650 | 7 | |a Cell-Free Nucleic Acids |2 NLM | |
| 700 | 1 | |a Moayedi, Yasbanoo |e verfasserin |4 aut | |
| 700 | 1 | |a Purewal, Saira |e verfasserin |4 aut | |
| 700 | 1 | |a Twiggs, Julien Valverde |e verfasserin |4 aut | |
| 700 | 1 | |a Waddell, Kian |e verfasserin |4 aut | |
| 700 | 1 | |a Luikart, Helen |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Jiho |e verfasserin |4 aut | |
| 700 | 1 | |a Feng, Kent |e verfasserin |4 aut | |
| 700 | 1 | |a Wayda, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Roy |e verfasserin |4 aut | |
| 700 | 1 | |a Shudo, Yasuhiro |e verfasserin |4 aut | |
| 700 | 1 | |a Jimenez, Shirin |e verfasserin |4 aut | |
| 700 | 1 | |a Khush, Kiran K |e verfasserin |4 aut | |
| 700 | 1 | |a Teuteberg, Jeffrey J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical transplantation |d 1987 |g 37(2023), 3 vom: 27. März, Seite e14699 |w (DE-627)NLM07493306X |x 1399-0012 |7 nnns |
| 773 | 1 | 8 | |g volume:37 |g year:2023 |g number:3 |g day:27 |g month:03 |g pages:e14699 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/ctr.14699 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 37 |j 2023 |e 3 |b 27 |c 03 |h e14699 | ||